Association of anticholinergic burden with adverse effects in older people with intellectual disabilities: an observational cross-sectional study.
cross_sectional · Level IV
Where this comes from
- Record sourced from PubMed, PMID 27660331.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
No studies to date have investigated cumulative anticholinergic exposure and its effects in adults with intellectual disabilities. To determine the cumulative exposure to anticholinergics and the factors associated with high exposure. A modified Anticholinergic Cognitive Burden (ACB) scale score was calculated for a representative cohort of 736 people over 40 years old with intellectual disabilities, and associations with demographic and clinical factors assessed. Age over 65 years was associated with higher exposure (ACB 1-4 odds ratio (OR) = 3.28, 95% CI 1.49-7.28, ACB 5+ OR = 3.08, 95% CI 1.20-7.63), as was a mental health condition (ACB 1-4 OR = 9.79, 95% CI 5.63-17.02, ACB 5+ OR = 23.74, 95% CI 12.29-45.83). Daytime drowsiness was associated with higher ACB (P<0.001) and chronic constipation reported more frequently (26.6% ACB 5+ v. 7.5% ACB 0, P<0.001). Older people with intellectual disabilities and with mental health conditions were exposed to high anticholinergic burden. This was associated with daytime dozing and constipation.
Medical subject headings
- Cholinergic Antagonists
- Drug-Related Side Effects and Adverse Reactions
- Intellectual Disability